Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics

Regeneron Pharmaceuticals, Inc. (REGN)

Today's Latest Price: $498.75 USD

2.10 (0.42%)

Updated Apr 2 4:00pm

Add REGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 337 in Biotech

See all "A" rated Strong Buy stocks

REGN Stock Summary

  • Regeneron Pharmaceuticals Inc's market capitalization of $49,457,204,740 is ahead of 96.98% of US-listed equities.
  • Price to trailing twelve month operating cash flow for REGN is currently 20.35, higher than 85.98% of US stocks with positive operating cash flow.
  • REGN's price/sales ratio is 6.29; that's higher than the P/S ratio of 86.58% of US stocks.
  • Stocks that are quantitatively similar to REGN, based on their financial statements, market capitalization, and price volatility, are LRCX, AMAT, MU, AMD, and VRTX.
  • REGN's SEC filings can be seen here. And to visit Regeneron Pharmaceuticals Inc's official web site, go to
REGN Daily Price Range
REGN 52-Week Price Range

REGN Stock Price Chart More Charts

REGN Price/Volume Stats

Current price $498.75 52-week high $518.00
Prev. close $496.65 52-week low $271.37
Day low $483.11 Volume 1,059,147
Day high $501.00 Avg. volume 1,280,698
50-day MA $425.66 Dividend yield N/A
200-day MA $347.73 Market Cap 54.87B

Regeneron Pharmaceuticals, Inc. (REGN) Company Bio

Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.

REGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Regeneron Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 43th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 9.5% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for REGN, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is 81.43 -- which is good for besting 92.9% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 5.63% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 62.58% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as REGN, try CRL, ARNA, GILD, ANGO, and ADMT.

REGN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

REGN Latest Social Stream

Loading social stream, please wait...

View Full REGN Social Stream

REGN Price Returns

1-mo 8.06%
3-mo 35.10%
6-mo 76.28%
1-year 22.54%
3-year 30.16%
5-year 13.80%
YTD 32.83%
2019 0.53%
2018 -0.65%
2017 2.42%
2016 -32.38%
2015 32.33%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7053 seconds.